Author information:
(1)Science for Life Laboratory, Division of Translational Medicine and Chemical 
Biology, Department of Medical Biochemistry and Biophysics.
(2)Clinical Proteomics Mass Spectrometry, Department of Oncology-Pathology.
(3)Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of 
Translational Medicine and Chemical Biology, Department of Medical Biochemistry 
and Biophysics.
(4)Division of Physiological Chemistry I, Department of Medical Biochemistry and 
Biophysics, Karolinska Institutet, Stockholm, Sweden.
(5)Molecular Carcinogenesis Group, Department of Histology and Embryology, 
School of Medicine, National and Kapodistrian University of Athens, Athens, 
Greece.
(6)Sahlgrenska Translational Melanoma Group (SATMEG), Sahlgrenska Cancer Center, 
Department of Surgery, Institute of Clinical Sciences, University of Gothenburg 
and Sahlgrenska University Hospital, Gothenburg.
(7)Department of Pharmacy and.
(8)Science for Life Laboratory Drug Discovery and Development Platform, ADME of 
Therapeutics facility, Department of Phamracy, Uppsala University, Uppsala, 
Sweden.
(9)Swedish Toxicology Sciences Research Center, Södertälje, Sweden.
(10)National Bioinformatics Infrastructure Sweden (NBIS), Science for Life 
Laboratory, Department of Medicine Solna, Karolinska Institutet, Stockholm.
(11)SP Process Development, Södertälje, Sweden.
(12)Uppsala Drug Optimisation and Pharmaceutical Profiling Platform (UDOPP), 
Department of Pharmacy, Uppsala University, Uppsala, Sweden.
(13)Institute of biomedical sciences, Academia Sinica, Taipei-115, Taiwan.
(14)Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
(15)Faculty Institute for Cancer Sciences, Manchester Academic Health Sciences 
Centre, University of Manchester, Manchester, UK.
(16)Science for Life Laboratory, Division of Translational Medicine and Chemical 
Biology, Department of Medical Biochemistry and Biophysics 
thomas.helleday@scilifelab.se.